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Cellular immortality and cancer: From telomerase to cancer stem cellsAfter two previous BACR (British Association for Cancer Research)
international meetings on telomerase and cancer stem cells held in
Northern Cyprus in 2004 and York, England in 2006, on June 3–4,
2008, a third conference was held in a relaxed atmosphere of the
Swan's Inn in Stratford-upon-Avon, England. At this meeting, the
participants discussed and evaluated progress and opportunities in
the normal stem cell and cancer stem cell areas. There was ample time
for discussions and cross-fertilization between ﬁelds. In particular, the
meeting focused on new ﬁndings in cellular self-renewal and cell
immortalization with a view to intervention strategies. Some of the
key presentations follow in this special issue of Biochimica et
Biophysicia Acta: Molecular Basis of Disease.
A variety of speciﬁc cancer types were discussed on this topic and
included prostate cancer, breast cancer, gliomas, hematopoietic
malignancies, and soft tissue sarcomas. Signiﬁcant recent advances
in our understanding of telomere biology and telomerase appeared to
be a common theme among many of the presentations. In addition to
normal and cancer stem cells, there were also discussions on human
diseases of aging such as Down's syndromes as well as diseases of
telomere dysfunction such as Dyskeratosis Congenita.
The large amount of discussions both after each talk and during the
breaks and social evening events was outstanding. This was probably
due to the outstanding speakers, a highly energized but small group of
participants (less than 80), as well as the vast amount of progress in
the ﬁeld of normal stem cells and cancer stem cells during the0925-4439/$ – see front matter © 2009 Published by Elsevier B.V.
doi:10.1016/j.bbadis.2009.03.006previous two years. As progress continues to be made, the connection
between telomerase, telomeres, and stem cell biology is becoming
more ﬁrmly established with rigorous experimental documentation.
Among the reviews that are covered in this special issue of BBA topic,
the following subjects are well represented in multiple contributions:
1. What mechanisms regulate self-renewal and differentiation in
normal stem cells and cancer stem cells?
2. How can we develop therapeutics that target cancer stem cells
without affecting normal stem cells?
3. What can we learn from telomerase as a target for therapeutic
development?
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W. Nicol Keith obtained his undergraduate training in
genetics at Edinburgh University before undertaking
his Ph.D. studies at the CRUK Beatson Institute for
Cancer Research in Glasgow. After post-doctoral
research in areas related to cancer drug resistance, he
established his research program in the Department
of Medical Oncology at Glasgow University. In
2004, he became Professor of Molecular Oncology at
the Centre for Oncology and Applied Pharmacology
of Glasgow University. Professor Keith's program
brings together the key strategic areas of cellular
immortality and senescence with the regulation of gene expression. The overall
objective of his work is to carry out translational research extending the
identification of basic mechanisms of gene regulation into validated targets for
new therapeutics. Telomerase activity is vital for tumor progression. Through
his research program, the group have discovered and characterized the key
promoter sequences, which switch on/off telomerase RNA gene expression.
This discovery has been used to develop a detailed understanding of the
molecular mechanisms influencing telomerase activity and how cancer cells
become immortal. Professor Keith's group focuses on exploiting their unique
understanding of cancer cell immortality to develop novel cancer therapeutics,
including small molecule drugs. His research is currently supported by grants
from Cancer Research UK, European Community, and Glasgow University.
Nicol is a member of several national and international scientific committees
and is particularly active within the International Union Against Cancer
(UICC), including chairing the UICC International Cancer Technology Transfer
Fellowships (ICRETT) grants committee, which facilitates rapid international
transfer of cancer research techniques and technology and clinical management
skills across the globe.
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Department of Cell Biology at The University of
Texas Southwestern Medical Center in Dallas, the
Associate Director of the Harold Simmon's Compre-
hensive Cancer Center, and holds the Southland
Corporation Distinguished Chair in Aging and
Cancer Research. Throughout his career, Dr. Shay
has been interested in the relationships between aging
and cancer. His seminal work on the relationships of
telomerase to aging and cancer has received much
international recognition. In 1995, he received the
AlliedSignal Award for Research on Aging, the 2001 American Association of
Aging Hayflick Award, from 1999 to 2003 was named an Ellison Medical
Foundation Senior Scholar in Aging Research, and in 2004 the Ted Nash
Foundation Award. In 2003, Dr. Shay was placed in the Institute for Scientific
Investigations as one of the most highly cited scientists in the field of Molecular
Biology and Genetics. In 2006, Science Watch placed Dr. Shay into the Doctors
of the Decade (1995–2005) list and he was ranked as the 6th most cited author
in the area of General Biomedicine (Science Watch 17:1 2–3, 2006). He has 35
papers that are each cited over 200 times and 60 additional research articles that
are cited over 100 times each. In addition to 19 issued patents, Dr. Shay has
published over 300 scientific articles, written 50 book chapters, and edited 10
books. Dr. Shay is on the editorial board of several scientific journals and is also
a member of biotechnology scientific advisory boards that focus on research in
cancer and aging. Finally, Dr. Shay serves as the Chairman of the Scientific
Review Committee for the Mary Kay Ash Charitable Foundation and is the
Program Director of the Cancer Biology Track for graduate students at UT
Southwestern.
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